The emergence of trastuzumab (Herceptin), a widely used monoclonal antibody (mAb) therapy that blocks HER2 signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC) toward HER2+ tumors, has significantly improved the survival rate of HER2+ carcinoma patients (2, 3, 4, 5). Here, ERBB2 is linked to carcinoma.